Oxidative Damage May Lead to Neurocognitive Decline
the Cancer Therapy Advisor take:
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood acute lymphoblastic leukemia (ALL), according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Researchers led by Peter Cole, MD, of the Albert Einstein College of Medicine examined genomic DNA that was isolated from bone marrow in 350 pediatric leukemia survivors.
“This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline,” they stated.
These polymorphisms were selected based on prior literature. Multivariable logistic regression models were used to estimate the association between genotype and neurocognitive outcomes.
They found that inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes (NOS3, SLCO2A1, and COMT) that were related to oxidative stress or neuroinflammation.
Oxidative damage may contribute to chemotherapy-associated neurocognitive decline in survivors of childhood ALL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma